Neuropediatrics 2016; 47(03): 162-168
DOI: 10.1055/s-0036-1582138
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Does Botulinum Toxin A Treatment Enhance the Walking Pattern in Idiopathic Toe-Walking?

Heli Sätilä
1   Department of Pediatric Neurology, Päijät-Häme Central Hospital, Lahti, Finland
2   Department of Pediatric Neurology, Kanta-Häme Central Hospital, Hämeenlinna, Finland
3   Department of Pediatric Neurology, Tampere University Hospital, Tampere, Finland
,
Anneli Beilmann
4   Department of Pediatric Neurology, Lappeenranta Central Hospital, Lappeenranta, Finland
,
Päivi Olsén
5   PEDEGO Research Unit (Research Unit for Pediatrics, Dermatology, Clinical Genetics, Obstetrics and Gynecology), Oulu University Hospital and University of Oulu, Oulu, Finland
,
Heli Helander
5   PEDEGO Research Unit (Research Unit for Pediatrics, Dermatology, Clinical Genetics, Obstetrics and Gynecology), Oulu University Hospital and University of Oulu, Oulu, Finland
,
Mari Eskelinen
6   Physiatric Department, Päijät-Häme Central Hospital, Lahti, Finland
,
Heini Huhtala
7   School of Health Sciences, University of Tampere, Tampere, Finland
› Author Affiliations
Further Information

Publication History

05 December 2015

15 February 2016

Publication Date:
18 April 2016 (online)

Abstract

Objective We conducted a randomized controlled trial to evaluate whether a combination of repeated botulinum toxin A (BTX-A) and conservative treatment is more effective in decreasing toe-walking than conservative treatment alone at 24 months follow-up.

Patients and Methods Children between 2 and 9 years of age were randomized either into the conservative (CO) or botulinum treatment (BTX) group. The treatment in the CO group consisted of firm shoes, night splints, a home stretching program and physiotherapy. The BTX arm had all the same conservative treatments added with calf muscle BTX-A injections repeated in 6 months intervals if needed. Change in toe-walking pattern, ankle range of movement (ROM), and overall function were assessed at baseline and 6, 12, 18, and 24 months posttreatment.

Results A total of 30 toe-walkers participated: 14 in CO and 16 in BTX group. At 24 months, all children in the BTX group and 85% in the CO group evaluated by the blinded physiotherapist (p = 0.065), 75% in the BTX group and 70% in the CO group graded by the research physiotherapist (p = 0.730), and 50% in the BTX group and 54% in the CO group reported by the parents ceased toe-walking (p = 0.837). The most prominent change was noted during the 1st year. The BTX group seemed to reach the goal earlier. No significant differences between the treatment groups in function or in ankle ROM ensued.

Conclusion Adding BTX injections did not significantly enhance the goal to walk either flat foot or with heel strike at 24 months posttreatment.

 
  • References

  • 1 Sutherland DH, Olshen R, Cooper L, Woo SL. The development of mature gait. J Bone Joint Surg Am 1980; 62 (3) 336-353
  • 2 Sala DA, Shulman LH, Kennedy RF, Grant AD, Chu ML. Idiopathic toe-walking: a review. Dev Med Child Neurol 1999; 41 (12) 846-848
  • 3 Engelbert R, Gorter JW, Uiterwaal C, van de Putte E, Helders P. Idiopathic toe-walking in children, adolescents and young adults: a matter of local or generalised stiffness?. BMC Musculoskelet Disord 2011; 12: 61
  • 4 Engström P, Tedroff K. The prevalence and course of idiopathic toe-walking in 5-year-old children. Pediatrics 2012; 130 (2) 279-284
  • 5 van Kuijk AA, Kosters R, Vugts M, Geurts AC. Treatment for idiopathic toe walking: a systematic review of the literature. J Rehabil Med 2014; 46 (10) 945-957
  • 6 Gormley ME, Herring GM, Gaebler-Spira D. The use of botulinum toxin in children: a retrospective study of adverse reactions and treatment of idiopathic toe-walking. Eur J Neurol 1997; 4 (Suppl. 02) S27-S30
  • 7 Jacks LK, Michels DM, Smith BP, Koman LA, Shilt J. Clinical usefulness of botulinum toxin in the lower extremity. Foot Ankle Clin 2004; 9 (2) 339-348
  • 8 Brunt D, Woo R, Kim HD, Ko MS, Senesac C, Li S. Effect of botulinum toxin type A on gait of children who are idiopathic toe-walkers. J Surg Orthop Adv 2004; 13 (3) 149-155
  • 9 Engström P, Gutierrez-Farewik EM, Bartonek A, Tedroff K, Orefelt C, Haglund-Åkerlind Y. Does botulinum toxin A improve the walking pattern in children with idiopathic toe-walking?. J Child Orthop 2010; 4 (4) 301-308
  • 10 Engström P, Bartonek Å, Tedroff K, Orefelt C, Haglund-Åkerlind Y, Gutierrez-Farewik EM. Botulinum toxin A does not improve the results of cast treatment for idiopathic toe-walking: a randomized controlled trial. J Bone Joint Surg Am 2013; 95 (5) 400-407
  • 11 World Health Organization. International classification of functioning, disability and health: children & youth version: ICF-CY. Geneva, Switzerland: WHO; 2001. . Available at: http://apps.who.int/iris/bitstream/10665/43737/1/9789241547321_eng.pdf . Accessed March 24, 2016
  • 12 Stricker SJ, Angulo JC. Idiopathic toe walking: a comparison of treatment methods. J Pediatr Orthop 1998; 18 (3) 289-293
  • 13 Hirsch G, Wagner B. The natural history of idiopathic toe-walking: a long-term follow-up of fourteen conservatively treated children. Acta Paediatr 2004; 93 (2) 196-199
  • 14 Williams C, Tinley PD, Curtin M, Nielsen S. Foot and ankle characteristics of children with an idiopathic toe-walking gait. J Am Podiatr Med Assoc 2013; 103 (5) 374-379
  • 15 Sobel E, Caselli MA, Velez Z. Effect of persistent toe walking on ankle equinus. Analysis of 60 idiopathic toe walkers. J Am Podiatr Med Assoc 1997; 87 (1) 17-22
  • 16 Eastwood DM, Menelaus MB, Dickens DR, Broughton NS, Cole WG. Idiopathic toe-walking: does treatment alter the natural history?. J Pediatr Orthop B 2000; 9 (1) 47-49
  • 17 Oetgen ME, Peden S. Idiopathic toe walking. J Am Acad Orthop Surg 2012; 20 (5) 292-300